
    
      This trial is designed to assess the efficacy and tolerability of mifepristone 5 mg given
      daily for 6 months to pre-menopausal women with symptomatic fibroids. The primary study
      outcome will be disease-specific quality of life. Secondary outcome measures include global
      quality of life, pain, bleeding, potential adverse effects, tumor size, and endometrial
      effects. The researchers will also examine a the effect of mifepristone on uterine blood
      flow. Randomization of study subjects will be stratified in order to ensure that equal
      numbers of women with moderate and severe symptoms will be enrolled in the placebo and
      control groups.
    
  